Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 10 2025
0mins
Should l Buy MREO?
Source: Benzinga
U.S. Stock Market Overview: U.S. stock futures are down, with the Dow futures dropping about 100 points; Methode Electronics reported a significant earnings miss, leading to a sharp decline in its shares despite a sales beat.
Notable Stock Movements: Several companies experienced pre-market trading declines, including Mereo BioPharma (-36.6%), Ultragenyx Pharmaceutical (-21.3%), and Wolfspeed (-11%), following various announcements and market reactions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.330
Low
0.50
Averages
2.08
High
5.00
Current: 0.330
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, aiming to recover damages for investors who purchased securities between June 5, 2023, and December 26, 2025, reflecting significant investor concern over the company's financial transparency.
- Allegations of Misrepresentation: The complaint alleges that Mereo provided overly optimistic statements to investors while concealing critical adverse facts regarding its Phase 3 ORBIT and COSMIC programs, leading to investor misconceptions about the company's prospects, which could negatively impact stock prices.
- Investor Action Deadline: Affected investors must request to be appointed as lead plaintiff by April 6, 2026, to share in any potential recovery, highlighting the urgency for investors to engage in the legal process to protect their interests.
- No-Cost Legal Representation: Bronstein, Gewirtz & Grossman, LLC offers contingency-based legal services, charging fees only upon successful recovery, which reduces the financial burden on investors and encourages more victims to seek legal recourse.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc must apply to be lead plaintiffs in the class action by April 6, 2026, to potentially receive compensation without any out-of-pocket costs, highlighting the urgency of the legal process and the potential benefits for investors.
- False Statements Allegations: The lawsuit alleges that defendants provided misleading positive expectations regarding setrusumab's performance in the Phase 3 Orbit and COSMIC studies, leading investors to purchase ADS at artificially inflated prices, reflecting serious deficiencies in the company's disclosure practices.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in handling such cases, which enhances investor confidence in their representation.
- Investor Action Recommendations: Investors can obtain more information by visiting the Rosen Law Firm's website or calling their toll-free number, emphasizing the importance of selecting qualified counsel to ensure effective protection of their rights in legal matters.
See More
Investors Encouraged to Claim Against Mereo BioPharma
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Mereo BioPharma Group plc, particularly for investors who purchased securities between June 5, 2023, and December 26, 2025, indicating possible legal risks.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing phone numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Mereo is April 6, 2026, emphasizing the importance of timely action.
- Legal Context: This investigation highlights the potential legal challenges facing Mereo BioPharma, prompting investors to remain vigilant in protecting their investment rights and seeking possible compensation.
See More
Class Action Lawsuit Filed Against Mereo BioPharma Group
- Class Action Initiation: Berger Montague PC has announced a class action lawsuit against Mereo BioPharma Group plc on behalf of investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's performance.
- Stock Price Collapse: Following Mereo's disclosure on December 29, 2025, that its ORBIT and COSMIC Phase 3 trials failed to meet primary endpoints, the ADS price plummeted over 87%, from $2.31 per share on December 26, 2025, to $0.29, severely undermining investor confidence.
- Investor Rights Notification: Investors must apply by April 6, 2026, to be appointed as lead plaintiff representatives in the class action, highlighting the urgency of the legal action and the emphasis on protecting investor rights.
- Company Background: Mereo, headquartered in London, focuses on developing therapies for rare and serious diseases, and this lawsuit could significantly impact its future financing and research and development plans.
See More
Class Action Filed Against Mereo BioPharma Group plc
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Mereo BioPharma Group plc, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by April 6, 2026, highlighting serious concerns over corporate governance and compliance.
- Stock Price Plunge: Following the announcement of progress in the Orbit study on July 10, 2025, Mereo's American Depositary Receipt (ADR) price fell by $1.25, or 42.52%, closing at $1.69, reflecting market disappointment over the clinical trial results and raising questions about the company's future prospects.
- Clinical Trial Failures: On December 29, 2025, Mereo disclosed that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, failing to meet primary endpoints, which resulted in a staggering $2.02 drop in ADR price, or 87.7%, closing at $0.29, severely impacting the company's market capitalization and investor confidence.
- Potential Legal Consequences: The class action lawsuit could expose Mereo to substantial damages, exacerbating its financial strain and potentially affecting its future fundraising capabilities, prompting investors to closely monitor developments to assess ongoing risks.
See More
Mereo BioPharma Faces Class Action Lawsuit Over Securities Fraud
- Class Action Initiated: Levi & Korsinsky LLP has notified investors in Mereo BioPharma Group plc of a class action lawsuit aimed at recovering losses for investors adversely affected by alleged securities fraud between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that defendants provided overwhelmingly positive statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, misleading investors about the company's true condition.
- Poor Study Results: On December 29, 2025, Mereo announced that neither the ORBIT nor COSMIC Phase 3 studies achieved statistical significance in reducing clinical fracture rates, despite improvements in bone mineral density, failing to meet their primary endpoints.
- Stock Price Plummets: Following the negative announcement, Mereo's ADS price fell dramatically from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7%, severely impacting investor interests.
See More
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, aiming to recover damages for investors who purchased securities between June 5, 2023, and December 26, 2025, reflecting significant investor concern over the company's financial transparency.
- Allegations of Misrepresentation: The complaint alleges that Mereo provided overly optimistic statements to investors while concealing critical adverse facts regarding its Phase 3 ORBIT and COSMIC programs, leading to investor misconceptions about the company's prospects, which could negatively impact stock prices.
- Investor Action Deadline: Affected investors must request to be appointed as lead plaintiff by April 6, 2026, to share in any potential recovery, highlighting the urgency for investors to engage in the legal process to protect their interests.
- No-Cost Legal Representation: Bronstein, Gewirtz & Grossman, LLC offers contingency-based legal services, charging fees only upon successful recovery, which reduces the financial burden on investors and encourages more victims to seek legal recourse.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc must apply to be lead plaintiffs in the class action by April 6, 2026, to potentially receive compensation without any out-of-pocket costs, highlighting the urgency of the legal process and the potential benefits for investors.
- False Statements Allegations: The lawsuit alleges that defendants provided misleading positive expectations regarding setrusumab's performance in the Phase 3 Orbit and COSMIC studies, leading investors to purchase ADS at artificially inflated prices, reflecting serious deficiencies in the company's disclosure practices.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in handling such cases, which enhances investor confidence in their representation.
- Investor Action Recommendations: Investors can obtain more information by visiting the Rosen Law Firm's website or calling their toll-free number, emphasizing the importance of selecting qualified counsel to ensure effective protection of their rights in legal matters.
See More
Investors Encouraged to Claim Against Mereo BioPharma
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Mereo BioPharma Group plc, particularly for investors who purchased securities between June 5, 2023, and December 26, 2025, indicating possible legal risks.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing phone numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Mereo is April 6, 2026, emphasizing the importance of timely action.
- Legal Context: This investigation highlights the potential legal challenges facing Mereo BioPharma, prompting investors to remain vigilant in protecting their investment rights and seeking possible compensation.
See More
Class Action Lawsuit Filed Against Mereo BioPharma Group
- Class Action Initiation: Berger Montague PC has announced a class action lawsuit against Mereo BioPharma Group plc on behalf of investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's performance.
- Stock Price Collapse: Following Mereo's disclosure on December 29, 2025, that its ORBIT and COSMIC Phase 3 trials failed to meet primary endpoints, the ADS price plummeted over 87%, from $2.31 per share on December 26, 2025, to $0.29, severely undermining investor confidence.
- Investor Rights Notification: Investors must apply by April 6, 2026, to be appointed as lead plaintiff representatives in the class action, highlighting the urgency of the legal action and the emphasis on protecting investor rights.
- Company Background: Mereo, headquartered in London, focuses on developing therapies for rare and serious diseases, and this lawsuit could significantly impact its future financing and research and development plans.
See More
Class Action Filed Against Mereo BioPharma Group plc
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Mereo BioPharma Group plc, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by April 6, 2026, highlighting serious concerns over corporate governance and compliance.
- Stock Price Plunge: Following the announcement of progress in the Orbit study on July 10, 2025, Mereo's American Depositary Receipt (ADR) price fell by $1.25, or 42.52%, closing at $1.69, reflecting market disappointment over the clinical trial results and raising questions about the company's future prospects.
- Clinical Trial Failures: On December 29, 2025, Mereo disclosed that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, failing to meet primary endpoints, which resulted in a staggering $2.02 drop in ADR price, or 87.7%, closing at $0.29, severely impacting the company's market capitalization and investor confidence.
- Potential Legal Consequences: The class action lawsuit could expose Mereo to substantial damages, exacerbating its financial strain and potentially affecting its future fundraising capabilities, prompting investors to closely monitor developments to assess ongoing risks.
See More
Mereo BioPharma Faces Class Action Lawsuit Over Securities Fraud
- Class Action Initiated: Levi & Korsinsky LLP has notified investors in Mereo BioPharma Group plc of a class action lawsuit aimed at recovering losses for investors adversely affected by alleged securities fraud between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that defendants provided overwhelmingly positive statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, misleading investors about the company's true condition.
- Poor Study Results: On December 29, 2025, Mereo announced that neither the ORBIT nor COSMIC Phase 3 studies achieved statistical significance in reducing clinical fracture rates, despite improvements in bone mineral density, failing to meet their primary endpoints.
- Stock Price Plummets: Following the negative announcement, Mereo's ADS price fell dramatically from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7%, severely impacting investor interests.
See More
